Literature DB >> 27890386

2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation.

Chern-En Chiang1, Tsu-Juey Wu2, Kwo-Chang Ueng3, Tze-Fan Chao4, Kuan-Cheng Chang5, Chun-Chieh Wang6, Yenn-Jiang Lin4, Wei-Hsian Yin7, Jen-Yuan Kuo8, Wei-Shiang Lin9, Chia-Ti Tsai10, Yen-Bin Liu11, Kun-Tai Lee12, Li-Jen Lin13, Lian-Yu Lin10, Kang-Ling Wang14, Yi-Jen Chen15, Mien-Cheng Chen16, Chen-Chuan Cheng17, Ming-Shien Wen6, Wen-Jone Chen18, Jyh-Hong Chen19, Wen-Ter Lai12, Chuen-Wang Chiou4, Jiunn-Lee Lin10, San-Jou Yeh20, Shih-Ann Chen21.   

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia. Both the incidence and prevalence of AF are increasing, and the burden of AF is becoming huge. Many innovative advances have emerged in the past decade for the diagnosis and management of AF, including a new scoring system for the prediction of stroke and bleeding events, the introduction of non-vitamin K antagonist oral anticoagulants and their special benefits in Asians, new rhythm- and rate-control concepts, optimal endpoints of rate control, upstream therapy, life-style modification to prevent AF recurrence, and new ablation techniques. The Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology aimed to update the information and have appointed a jointed writing committee for new AF guidelines. The writing committee members comprehensively reviewed and summarized the literature, and completed the 2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the Management of Atrial Fibrillation. This guideline presents the details of the updated recommendations, along with their background and rationale, focusing on data unique for Asians. The guidelines are not mandatory, and members of the writing committee fully realize that treatment of AF should be individualized. The physician's decision remains most important in AF management. Copyright Â
© 2016. Published by Elsevier B.V.

Entities:  

Keywords:  ablation; antiarrhythmic agents; anticoagulation; atrial fibrillation; non-vitamin K antagonist oral anticoagulant; vitamin K antagonist

Mesh:

Substances:

Year:  2016        PMID: 27890386     DOI: 10.1016/j.jfma.2016.10.005

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  41 in total

1.  Successful Resolution of Left Ventricular Thrombus after ST-Elevation Myocardial Infarction by Edoxaban in a Patient with High Bleeding Risk.

Authors:  Kei-Ip Cheong; Wen-Po Chuang; Yen-Wen Wu; Shan-Huei Huang
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672

2.  Combination of Oral Anticoagulants and Single Antiplatelets versus Triple Therapy in Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome: Stroke Prevention among Asians.

Authors:  Anwar Santoso; Sunu B Raharjo
Journal:  Int J Angiol       Date:  2020-05-06

3.  Dynamic stroke risk scores of atrial fibrillation.

Authors:  Minjae Yoon; Boyoung Joung
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

4.  Health Economics of Stroke Prevention in Atrial Fibrillation.

Authors:  Kang-Ling Wang; Chern-En Chiang
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

5.  A Brave New World.

Authors:  Kang-Ling Wang; Chern-En Chiang
Journal:  Acta Cardiol Sin       Date:  2019-09       Impact factor: 2.672

6.  Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.

Authors:  Lai-Chu See; Hsin-Fu Lee; Tze-Fan Chao; Pei-Ru Li; Jia-Rou Liu; Lung-Sheng Wu; Shang-Hung Chang; Yung-Hsin Yeh; Chi-Tai Kuo; Yi-Hsin Chan; Gregory Y H Lip
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-19       Impact factor: 3.727

7.  Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.

Authors:  Chieh-Yu Liu; Hui-Chun Chen
Journal:  Cardiol J       Date:  2018-05-02       Impact factor: 2.737

8.  Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation.

Authors:  Shih-Wei Meng; Ting-Tse Lin; Min-Tsun Liao; Ho-Min Chen; Chao-Lun Lai
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672

9.  Comparison of Arrhythmia Detection by 24-Hour Holter and 14-Day Continuous Electrocardiography Patch Monitoring.

Authors:  Su-Kiat Chua; Lung-Ching Chen; Li-Ming Lien; Huey-Ming Lo; Zhen-Yu Liao; Shu-Ping Chao; Cheng-Yen Chuang; Chiung-Zuan Chiu
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

10.  Echocardiographic Evaluation of Left Atrial Function to Discriminate Non-Valvular Atrial Fibrillation Development in Patients with Apical Hypertrophic Cardiomyopathy.

Authors:  Yu-Cheng Kao; Ming-Jui Hung
Journal:  Acta Cardiol Sin       Date:  2020-01       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.